On Jan. 31, biopharmaceutical company Gilead Sciences
- Product sales increased by 55.7% to $768.1 million, primarily thanks to a 67% increase in the HIV product franchise and the strong performance of the Atripla and Truvada drugs.
- The company incurred a net loss of $1.65 billion because of a $2 billion charge related to the acquisitions of Corus and Myogen.
- Cash, cash equivalents, and marketable securities decreased by 39.9% to $1.39 billion, primarily because of $2.74 billion in net cash paid for the acquisitions of Myogen, Corus, and Raylo Chemicals.
- Gilead is a very popular stock in Motley Fool CAPS, with 96% of players who have rated the company giving it an "outperform."
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change |
|
|---|---|---|---|
|
Sales |
$899.2 |
$609.3 |
47.6% |
|
Net Profit |
($1,665.6) |
$281.6 |
N/A |
|
EPS |
($3.62) |
$0.59 |
N/A |
|
Diluted Shares |
460.1 |
479.2 |
(4.0%) |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
82.7% |
87.8% |
(5.1) |
|
Operating Margin |
(172.7%) |
59.1% |
(231.8) |
|
Net Margin |
(185.2%) |
46.1% |
(231.4) |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$1,389.6 |
$2,311.0 |
(39.9%) |
|
Accounts Rec. |
No Data |
No Data |
No Data |
|
Inventory |
$564.1 |
$216.9 |
160.1% |
No data provided for liabilities.
Learn the ways of the balance sheet.
Cash Flow Highlights
No data provided for cash flow. Boo!
Find out why Fools always follow the money.
Related Companies:
-
Panacos Pharmaceuticals
(NASDAQ:PANC) -
Vertex Pharmaceuticals
(NASDAQ:VRTX) -
Celgene
(NASDAQ:CELG) -
Biogen Idec
(NASDAQ:BIIB) -
Genzyme
(NASDAQ:GENZ)
Related Foolishness:
Panacos Pharmaceuticals and Vertex Pharmaceuticals are Motley Fool Rule Breakers recommendations. Biogen Idec is a Stock Advisor pick.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
